Navigation Links
PLC Systems Announces Approval of First European Study to Evaluate RenalGuard(TM)
Date:5/30/2008

Trial designed to evaluate effectiveness of device in preventing

Contrast-Induced Nephropathy

FRANKLIN, Mass., May 30 /PRNewswire-FirstCall/ -- PLC Systems Inc. (Amex: PLC), a company focused on innovative cardiac and vascular medical device-based technologies, announced today that the ethics committee of the Centro Cardiologico Monzino (CCM-University of Milan), Milan, Italy has approved the planned randomized clinical trial to evaluate the use of RenalGuard(TM) in the prevention of Contrast-Induced Nephropathy (CIN) in high-risk patients undergoing catheterization procedures at its institution.

The investigators for the trial are Dr. Antonio L. Bartorelli, Director, Interventional Cardiology, CCM, and Professor of Cardiology, University of Milan, and Dr. Giancarlo Marenzi, Chief, Intensive Cardiac Care Unit, CCM, who are two of the world's leading experts in the prevention of CIN.

PLC's President and Chief Executive Officer, Mark R. Tauscher, said, "We are very pleased that this study has received approval from CCM's ethics committee. We anticipate that this study will greatly increase the visibility of our RenalGuard System in Europe, and that the data gathered from the study will enable us to seek expanded claims in order to market RenalGuard as a CIN prevention device throughout the European Union."

The trial is designed as a prospective, open, randomized trial to provide an assessment of the potential benefits of induced diuresis with matched hydration therapy, compared to standard overnight hydration, in the prevention of CIN in patients undergoing cardiac catheterization procedures and percutaneous coronary interventions with baseline impairment in renal function. The CIN-prev
'/>"/>

SOURCE PLC Systems Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
2. PLC Systems Reports Fourth Quarter 2007 Results
3. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
4. PLC Medical Systems Names Lead Investigators for Pivotal Trial to Evaluate RenalGuard System(TM) and RenalGuard Therapy(TM)
5. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
6. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
7. Imaging Diagnostic Systems CTLM Technology Presented at Congress of World Society for Breast Health
8. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
9. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
10. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
11. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... YORK , July 25, 2014  Smile Train ... to showcase their Virtual Surgery Simulator among leading ... which will take place in Washington, D.C. ... the Performing Arts. "Smile Train is ... alongside the talented community of innovators in health and ...
(Date:7/25/2014)... 2014 GrowBLOX Sciences, Inc. (OTCQB: GBLX) is pleased ... ("MOU") with LaurelCo, LLC, an Illinois ... cultivation and dispensary medical marijuana licenses in the state of ... will acquire a 20% equity interest in LaurelCo, LLC in ... growing chambers, as well as all technology related to the ...
(Date:7/25/2014)...  Solanbridge Group Inc (OTC: SLNX) is pleased to ... Buzznbrewz.com and the Letter of Intent issued on July ... Purchase Agreement. Charles R. Shirley , ... have Mr. David Pecoraro and Buzznbrewz.com join ... private sector and developed a tremendous network of contacts ...
Breaking Medicine Technology:Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 3GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2
... 2011 Caliper Life Sciences, Inc. (NASDAQ: ... for life science companies, today announced that Kevin Hrusovsky, President ... BioConference Live event, which was held on October 26, and ... Forum on October 27 held at Harvard Medical School. ...
... Conn., Nov. 7, 2011 Boehringer Ingelheim Pharmaceuticals, Inc. ... a Phase 2b study, SOUND-C2, that showed the combination ... compounds – the protease inhibitor BI 201335 and the ... successful in reducing viral load below the lower limit ...
Cached Medicine Technology:Caliper CEO Kevin Hrusovsky Presented Vision for Revolutionizing Medicine 2Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 2Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 3Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 4Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 5
(Date:7/28/2014)... July 28, 2014 According to court documents, ... owner of The Marcal Group (TMG), met with ... (HMG). A contract, as well a broad project outline, were ... as well as branding services and marketing. , ... by HMG throughout the course of the project, praise was ...
(Date:7/28/2014)... Downers Grove, IL (PRWEB) July 28, 2014 ... marketing company for mental health professionals, announced today its ... Family Therapy (IAMFT). This new relationship allows TherapySites ... IAMFT members, adding exclusive benefits and promotional offers. , ... business is being done today. With nearly 3 ...
(Date:7/28/2014)... July 28, 2014 According to the Heartburn ... a comprehensive guide that will help people get rid of ... all the necessary information about heartburn and acid reflux. In ... about heartburn , and risk factors for reflux disease. ... help people get rid of symptoms of reflux disease naturally ...
(Date:7/28/2014)... July 28, 2014 Shore Points Capital ... its investment in Loftware, Inc., through a recapitalization of ... Points was the lead investor in Loftware for over ... become the leading international provider of enterprise level software ... been a great investment for us, and we are ...
(Date:7/27/2014)... 2014 Hyaluronic Acid can hold 1,000 ... key to the power of Hyaluronic Serums. , "Hyaluronic ... founder of Sublime Beauty®. "But like collagen, it diminishes ... ours improves skin moisture-retention and radiance." , Hyaluronic ... a healthy and beautiful look. Key Ingredients in the ...
Breaking Medicine News(10 mins):Health News:Calko Medical Center Loses Website Twice over Non-Payment, According to Court Documents 2Health News:TherapySites (Websites for Therapists) Partners with the Illinois Association for Marriage and Family Therapy 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3Health News:Shore Points Capital Announces Sale of Portfolio Company Loftware 2Health News:Aging or Dry Skin Benefits from Hyaluronic Serum; Now 30% Off Sale at Sublime Beauty® 2
... over past 20 years due to suffocation, strangulation , ... accidental injury or death associated with crib bumper pads ... University School of Medicine in St. Louis. , Many ... protect babies from injury. But the researchers reviewed U.S. ...
... 2007 Late-breaking results from the ENDEAVOR IV trial, ... the Cardiovascular Research Foundation, show that the Endeavor zotarolimus-eluting ... overall safety profile (equivalent rates of death, heart attack, ... 1 year. , In addition, the Endeavor stent ...
... Lack Proper Healthcare Coverage, SAN FRANCISCO, ... Chapter of Autism Speaks today announced the ... Commission on,Autism,s recommendations to ensure appropriate and ... These recommendations were,finalized and presented to the ...
... MINNEAPOLIS, Oct. 22 Building upon its impressive ... laying out,a global vision, which will propel it ... orthopaedic research, education and new product,innovation, will solidify ... Over the next year, MORF will be ...
... than 450 people gathered on,Tuesday, October 9, at The ... 18th Annual CATCH Night of Champions. The event,featured a ... ceremony. The,event raised $225,000, with more than $38,000 raised ... been a major supporter of the charity since,1989, and ...
... has significantly increased life expectancy in early tests of ... most aggressive form of brain cancer in adults − ... Mayo Clinic in Jacksonville. , The vaccine represents a ... says neurosurgeon Kent New, M.D., Ph.D., who will be ...
Cached Medicine News:Health News:Crib Bumper Pads Too Risky for Baby 2Health News:ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent 2Health News:San Francisco Bay Area Autism Speaks Chapter Endorses Blue Ribbon Commission on Autism Recommendations for Equitable Insurance Coverage for Children With Autism 2Health News:San Francisco Bay Area Autism Speaks Chapter Endorses Blue Ribbon Commission on Autism Recommendations for Equitable Insurance Coverage for Children With Autism 3Health News:Mayo Clinic tests novel vaccine for aggressive brain tumors 2
... The Angio-Seal vascular closure device ... following catheterization procedures, allowing for ... The device creates a mechanical ... between a bio-absorbable anchor and ...
Terumo's Optitorque offers superior torque and precision control. It's patient-friendly, high torque design makes it the catheter of choice for demanding angiography....
Femoral selective catheter. Catheter material used is polyurethane (DUCOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Medicine Products: